News

Deal Announcements

Allozyne Closes $30 Million In Second Round Funding

Monday, October 29, 2007 5:00:00 AM PDT | VentureDeal Staff
SEATTLE, WA -- Biotechnology company Allozyne, Inc. said that it has successfully closed its series B financing, receiving $30 million in new investment from a syndicate of venture capital firms and a strategic investor.

Allozyne is focused on modifying recombinant proteins and monoclonal antibodies in the hope that their research will result in improved efficacy of protein-based therapeutics.

Investors in the round included lead investor MPM Capital, OVP Venture Partners, ARCH Venture Partners, Amgen Ventures and Alexandria Real Estate Equities.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1